EUCTR2016-002667-34-IT进行中（未招募）1 期
AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY,TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSINGREMITTINGMULTIPLE SCLEROSIS - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizum
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Able to comply with the study protocol, in the investigator's judgment
- •- Age at screening between >= 10 and < 18 years
- •- Body weight >= 25 kg note:enrollment of Pt with a body weight>=50kg is closed
- •- Children and adolescents must have received all childhood required vaccinations as per local/national recommendations for childhood vaccination against infectious diseases calendar of immunization
- •- For female patients of childbearing potential: agreement to remain abstinent or use contraception. Adherence to local requirement, if more stringent, is required
- •Inclusion Criteria Related to Pediatric MS:
- •- Diagnosis of relapsing-remitting multiple sclerosis (RRMS) in accordance with the International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric MS, Version 2012, and McDonald criteria 2017
- •Expanded Disability Status Scale (EDSS) at screening: 0-5.5, inclusive
- •- Neurologic stability for >= 30 days prior to screening, and between screening and baseline
- •- Patients naïve to prior disease-modifying therapy (DMT) or patients
- •who have had less than a total of 6 months of DMT within the past 1 year
- •must have one of the following:
- •o At least two relapses in the last 2 years, with at least one relapse
- •experienced in the previous year
- •o At least two relapses in the last 2 years and >= 1 Gd-enhancing
- •lesion(s) (silent or not) on T1-weighted brain MRI at any time within the
- •previous year
- •o At least one relapse in the previous year and >= 1 Gd-enhancing
- •lesion(s) on T1-weighted brain MRI at any time within the last year
- •- Patients who have had at least 6 contiguous months of DMT within the
- •past 1 year must have evidence of disease activity occurring after the
- •full 6-month course of treatment, that is, at least one relapse or >= 1 Gd-enhancing lesion(s) on a T1-weighted brain MRI
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Excl Related to General Health:-Pregn or lactation-Known pres or suspicion of other neurol disorders that may mimic MS,includ,but not limited to,acute disseminated encephalomyelitis,andneuromyelitis optica or neuromyelitis optica spectrum disorders and any neurol,somatic or metab condit that cloud interfere with brain function or normal cognitiv or neurol develop.-Pt that are aquaporin 4 posit and myelin oligodendrocyte glycoprot(MOG)antib posit are not eligib to participate in study.-In case of ADEM-like appearance of the 1°MS attack, a 2°attack with clear MS-like feature is required.- Signif or uncontrol somatic diseases or any other signif condition that may preclude pt from participating in study-Known active bact,viral,fung,mycobacterial infect,or other infect,excluding fung infect of nail beds-Infect requiring hospit or treatm with IV anti-infectiveagents within 4 wks prior to baseline visit or oral anti-infect agents within 2 wks prior to baseline visit-History or known presence of recurrent or chronic infection(e.g.,HIV,syphilis,tuberculosis)-Receipt of a live or live-attenuated vaccine within 6 wks prior treatm allocation.Pt's vaccination record and a need forimmunization should be carefully reviewed- History or lab evidence of coagul disorders-Peripheral venous access that precludes IV administr and venous blood sampling as required per study protocol-Inability to complete an magn reson imaging(MRI)scan-Teeth braces interfering with MRI acquisition-History of cancer,including solid tumors,hemat malignancies,and carcinoma in situ(except basal cell and squamous cell carcinoma ofthe skin that have been excised and cured)-Current active alcohol or drug abuse or hist of alcohol or drug abuse.Exclus Related to Med:-Hist of a severe allergic or anaphylactic react to humanized or murine monocl antibody(mAbs)or known hypersensitivity to any component of ocreliz solution-Contraindications to or intolerance of oral or IV corticosteroids,antihistaminics,or antipyretics according to the country label-Treat with any investigational agent within 24 wks of screen or 5 half-lives,whichever is longer-Previous treatm with B-cell-targeted therapies-Any previous treatm with alemtuz, anti-CD4,cladribine,mitoxantrone,dacliz, laquinimod, total body irradiation,or bone marrow transplantation-Treatm with cyclophos, azathiop, mycophenolatemofetil,cyclospo,methotrex,or nataliz within 24 months prior to treatm alloc-Treatm with teriflun,fingolimod,or other S1P receptor modulator(e.g.,BAF312/siponimod)within 24 wks prior to treatm allocat-Treatm with fingolimod within 6 weeks prior to treatm alloc and lymphoc count<LLN for age-and sex-specif ref range treatm with any other S1P receptor modulator(e.g.BAF312/siponimod)within 24 wks prior to treatm alloc-Treatm with dimethyl fumarate within 4 wks prior to treatm alloc and lynph count <LLN for age-and sex-specific reference range-Treatm with IVIg within 12 wks prior to treatm alloc-Treatm with plasmapheresis within 4 wks prior to treatm alloc-Systemic corticost therapy within 6 wks prior to treatm alloc.Exclus Related to Lab Findings:-Posit serum beta-human chorionic growth hormone(ß-hCG)measured at screen or posit pregn test prior to first infusion of ocreliz-Posit screen tests for hepatitis B (hepat B surface antigen[HBsAg]posit, or positive hepat B core antibody[tot HBcAb]confirmed by a posit viral DNA polymerase chain reaction [PCR]) orhepatitis C antibody (HepCAb)-Posit rapid plasma reagin if confirmed
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple SclerosisRelapsing-remitting multiple sclerosis (MS)MedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002667-34-PLF. Hoffmann-La Roche Ltd36
进行中（未招募）
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple Sclerosis (RRMS)MedDRA version: 20.1Level: LLTClassification code: 10039720Term: Sclerosis multiple Class: 10029205MedDRA version: 21.1Level: PTClassification code: 10063399Term: Relapsing-remitting multiple sclerosis Class: 100000004852CTIS2023-507313-94-00F. Hoffmann-La Roche AG24
进行中（未招募）
不适用
Pharmacokinetics and Safety of Doripenem in hospitalized Pediatric Patients from 3 Months to 17 Years of AgeBacterial infectionsEUCTR2011-005159-15-Outside-EU/EEAJohnson & Johnson Pharmaceutical Research & Development, L.L.C.50
进行中（未招募）
1 期
A study to evaluate the effectiveness and safety of a study drug called vadadustat in the maintenance treatment of anemia for children, naïve to ESA therapyAnemia of Chronic kidney disease (CKD)MedDRA version: 20.0Level: LLTClassification code 10002272Term: AnemiaSystem Organ Class: 100000004851MedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-003994-72-ESAkebia Therapeutics, Inc.71
进行中（未招募）
1 期
A study to evaluate the effectiveness and safety of a study drug called vadadustat in the maintenance treatment of anemia for children, after they've converted from ESA therapyAnemia of Chronic kidney disease (CKD)MedDRA version: 20.0Level: LLTClassification code 10002272Term: AnemiaSystem Organ Class: 100000004851MedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-004022-30-ESAkebia Therapeutics, Inc.71